proadrenomedullin

10/30/2019 - "Midregional proadrenomedullin (MR‑proADM) shows promising results as an outcome predictor in patients with sepsis. "
03/21/2018 - "The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial."
08/29/2022 - "Mid-regional proadrenomedullin (MR-proADM) protects against endothelial permeability and has been associated with prognosis in bacterial sepsis. "
02/01/2022 - "The Role of Mid-Regional Proadrenomedullin in the Differential Diagnosis between Culture-Negative and Culture-Positive Sepsis at Emergency Department Admission."
01/01/2022 - "What is New: • Proadrenomedullin is increased in neonates with sepsis. "

01/01/2022 - "Kinetics of copeptin and mid regional proadrenomedullin (MR-proADM) during febrile pediatric lower respiratory tract infections (LRTI) are unknown. "
01/01/2022 - "The kinetic profiles of copeptin and mid regional proadrenomedullin (MR-proADM) in pediatric lower respiratory tract infections."
05/03/2011 - "Proadrenomedullin (ProADM) confers additional prognostic information to established clinical risk scores in lower respiratory tract infections (LRTI). "
05/03/2011 - "Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm."
11/29/2012 - "The aim of this study was to determine the prognostic utility of serial measurement of the cardiovascular biomarker midregion proadrenomedullin (MR-proADM) in patients admitted with lower respiratory tract infection. "

03/01/2016 - "Procalcitonin and MR-proAdrenomedullin combined score in the diagnosis and prognosis of systemic and localized bacterial infections."
08/01/2012 - "Markers such as lactate for risk stratification and guidance of fluid resuscitation, procalcitonin for assessing risk of bacterial infections and guiding therapeutic decisions about initiation and duration of antimicrobial therapy, and recently proadrenomedullin for early mortality prediction and site-of-care decisions in respiratory infections, have shown to improve patient management. "

08/19/2015 - "Proadrenomedullin and copeptin in pediatric pneumonia: a prospective diagnostic accuracy study."
10/04/2023 - "Red cell distribution width as a prognostic marker for complications of community-acquired pneumonia in children: a comparison with Proadrenomedullin and Copeptin."
12/01/2021 - "Urinary Proadrenomedullin and Disease Severity in Children With Suspected Community-acquired Pneumonia."
10/05/2021 - "Proadrenomedullin in Mycoplasma pneumoniae Community-Acquired Pneumonia in Children."
01/01/2021 - "Proadrenomedullin Predicts Severe Disease in Children With Suspected Community-acquired Pneumonia."

08/04/2022 - "After Pubmed, Embase, and Scopus search, registries, and gray literature, deduplication, and selection of full-texts, we found 21 studies addressing the use of proadrenomedullin in COVID-19. "
01/01/2022 - "The aim of this study was to evaluate whether the association of myocardial injury and elevated mid-regional proAdrenomedullin values could predict mortality of SARS-CoV-2 patients, to offer the best management to COVID-19 patients. "
01/01/2022 - "The aim of the study was to assess the role of mid-regional proadrenomedullin (MR-proADM) in comparison with routine laboratory tests in patients with COVID-19. "
09/01/2021 - "The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19. "
08/31/2023 - "It has been reported that mid-regional proadrenomedullin (MR-proADM) could be considered a useful tool to stratify the mortality risk in COVID-19 patients upon admission to the emergency department (ED). "